An interventional study of Young Adults Coping with Cancer Together Intervention in Cancer, Survivorship and Caregiver Burden, sponsored by Massachusetts General Hospital. Completed at 4 sites in United States. Open to participants aged 25 Years to 39 Years. Per ClinicalTrials.gov, last updated 2026-10-05.
Sponsored by Massachusetts General Hospital · Not applicable, Interventional, and Supportive care
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The purpose of this pilot study is to examine the feasibility and acceptability of a brief psychotherapy intervention to improve psychosocial coping and maintain couple relationships among young adults (aged 25-39) with cancer and their caregiving partners.
Young adults (YA) with cancer have unique challenges in coping, and their primary partners may experience burden and low self-efficacy related to caregiving. In this single-arm pilot trial, the investigators shall deliver an eight-session intervention to YAs with cancer and their self-identified partners who provide caregiving. The intervention is founded on principles from cognitive-behavioral therapy and couples-focused interventions, tailored for YA. The aim of the study is to assess the feasibility and acceptability of the intervention, which will inform refinements prior to a larger-scale clinical trial. This study will include 10 YAs and their partner-caregivers (N=20). Participants will complete surveys at baseline and after the intervention, and will be invited to complete optional semi-structured exit interviews.
10,838 studies on the registry are indexed under Neoplasms; 2,322 are open to participants now.
This study's enrollment of 20 is below the median of 60 across 7,716 interventional studies indexed under Neoplasms.
Browse Neoplasms studies →Massachusetts General Hospital is the lead sponsor of 2,591 studies on the registry; 445 are open to participants now.
Of its 224 completed or terminated interventional studies of FDA-regulated products, 168 (75%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Young adults with cancer and their partner-caregivers will attend dyadic virtual psychotherapy sessions lasting 45-60 minutes on a weekly basis for eight weeks.
Behavioral: Young Adults Coping with Cancer Together Intervention
This intervention is based on cognitive-behavioral therapy and couples' therapy. It aims to improve cancer and caregiving-related self-efficacy and coping, as well as promote relationship maintenance in context of cancer. The intervention will be delivered by a trained mental health practitioner and include didactics, experiential exercises, and home practice.
Also known as: YAD Intervention
Feasibility of Intervention
Feasibility will be measured by participant rates of enrollment (≥50% of eligible participants enroll), participant retention (≥70% complete the 14-week post-baseline assessment), and intervention attendance (≥70% of participants attending at least 6 of 8 sessions).
Time frame: 14 +/- 2 Weeks
Acceptability of Intervention
Acceptability with be measured by satisfaction with the intervention as rated on the Client Satisfaction Questionnaire. The intervention will be deemed acceptable if ≥75% of participants report average satisfaction that exceeds the CSQ's midpoint.
Time frame: 14 +/- 2 Weeks
From April 2024 to January 2026, study staff invited young adult patients and their partner cargeivers to participate in the young adult dyadic (YAD) intervention. This study was conducted at the Mass General Brigham Cancer Institute (MGBCI) and three community affiliates. Study staff identified potentially eligible patients through electronic health record review from the participating site's oncology clinics and approached during outpatient appointments or via telephone.
| Milestone | Young Adults Dyadic (YAD) Intervention - Patient Participants | Young Adults Dyadic (YAD) Intervention - Partner Caregiver Participants |
|---|---|---|
| Started | 10 | 10 |
| Completed | 10 | 10 |
| Not completed | 0 | 0 |
Feasibility will be measured by participant rates of enrollment (≥50% of eligible participants enroll), participant retention (≥70% complete the 14-week post-baseline assessment), and intervention attendance (≥70% of participants attending at least 6 of 8 sessions).
| Participants | Young Adults Dyadic (YAD) Intervention - Patient Participants | Young Adults Dyadic (YAD) Intervention - Partner Caregiver Participants |
|---|---|---|
| Enrollment Feasibility | 10 | 10 |
| Retention Feasibility | 10 | 10 |
| Attendance Feasibility | 10 | 10 |
Acceptability with be measured by satisfaction with the intervention as rated on the Client Satisfaction Questionnaire. The intervention will be deemed acceptable if ≥75% of participants report average satisfaction that exceeds the CSQ's midpoint.
| Participants | Young Adults Dyadic (YAD) Intervention - Patient Participants | Young Adults Dyadic (YAD) Intervention - Partner Caregiver Participants |
|---|---|---|
| Acceptability of Intervention | 10 | 10 |
Collected over Adverse event data was collected from enrollment until end of follow-up, up to 16 weeks.. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Young Adults Dyadic (YAD) Intervention - Patient Participants | 0/10 (0%) | 0/10 (0%) | 0/10 (0%) |
| Young Adults Dyadic (YAD) Intervention - Partner Caregiver Participants | 0/10 (0%) | 0/10 (0%) | 0/10 (0%) |
No participants were excluded from analyses at baseline.
| Age, Continuous(Years) | Young Adults Dyadic (YAD) Intervention - Patient Participants | Young Adults Dyadic (YAD) Intervention - Partner Caregiver Participants | Total |
|---|---|---|---|
| Mean | 33.64 ± 3.24 | 35.26 ± 5.46 | 34.45 ± 4.45 |
| Sex/Gender, Customized(Participants) | Young Adults Dyadic (YAD) Intervention - Patient Participants | Young Adults Dyadic (YAD) Intervention - Partner Caregiver Participants | Total |
|---|---|---|---|
| Gender — Woman | 6 | 2 | 8 |
| Gender — Man | 2 | 7 | 9 |
| Gender — Non-binary | 1 | 1 | 2 |
| Gender — Declined to respond | 1 | 0 | 1 |
| Race/Ethnicity, Customized(Participants) | Young Adults Dyadic (YAD) Intervention - Patient Participants | Young Adults Dyadic (YAD) Intervention - Partner Caregiver Participants | Total |
|---|---|---|---|
| Race — White or of European Background | 8 | 10 | 18 |
| Race — Asian, Asian American or of Asian background | 1 | 0 | 1 |
| Race — Option not listed | 1 | 0 | 1 |
| Race/Ethnicity, Customized(Participants) | Young Adults Dyadic (YAD) Intervention - Patient Participants | Young Adults Dyadic (YAD) Intervention - Partner Caregiver Participants | Total |
|---|---|---|---|
| Ethnicity — Not Hispanic or Latino/a/x | 10 | 8 | 18 |
| Ethnicity — Declined to respond | 0 | 2 | 2 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — The Dana-Farber / Harvard Cancer Center encourages and supports the responsible and ethical sharing of data from clinical trials. De-identified participant data from the final research dataset used in the published manuscript may only be shared under the terms of a Data Use Agreement. Requests may be directed to: jjacobs@mgh.harvard.edu. The protocol and statistical analysis plan will be made available on Clinicaltrials.gov only as required by federal regulation or as a condition of awards and agreements supporting the research.
Supporting information: Study protocol, Statistical analysis plan, Informed consent form
Time frame: Data can be shared no earlier than 1 year following the date of publication
Access criteria: Contact the Partners Innovations team
Data sharing details ↗ · www.massgeneralbrigham.org
Ran from Apr 2024 to primary completion in Apr 2026, 24 months.
Results were first posted in Oct 2026, 5 months after primary completion.
Of 1,993 non-industry interventional studies with no phase under Neoplasms, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 52. This study's 24 months is below that.
Counting every sponsor, half of 2,068 studies reached it within 29 months; a quarter within 13 and three quarters within 52.
Neoplasms covers many different conditions, not one, so the studies compared here vary widely. Read these figures as a rough guide.
Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 5, 2026: primary completion Jun 2026 → Apr 2026 and completion Dec 2026 → Apr 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Massachusetts General Hospital →